USING LIVE, RECOMBINANT BAKERS YEAST AS AN HIV VACCINE

描述：(摘自申请者摘要)细胞毒性T细胞(CTL) 免疫被认为在早期减少病毒载量方面起着重要作用。 在艾滋病毒感染和减缓向艾滋病发展的速度方面。 然而，目前大多数HIV疫苗已进入人类临床高级阶段 那些由艾滋病毒衍生蛋白或灭活病毒组成的试验引发了 抗体反应强，但诱导CTL介导的免疫效果差。 我们开发了一种新的疫苗输送系统，名为HIVAX， 由非致病面包师S酵母(酿酒酵母)组成 我们已经设计了表达HIV-1 gp160包膜蛋白的基因。 对老鼠和猪尾猕猴的初步研究揭示了几个 我们疫苗的重要特点：1)它刺激CTL- 中介免疫和体液免疫；2)不需要联合用药 佐剂；3)它不含传染性物质；4)它似乎 口服时可免疫；5)可利用重组 表达三种或三种以上蛋白质抗原的DNA技术。 在这项提案中，研究人员将：1)确定疫苗是否 通过显示肿瘤细胞表达对小鼠的保护性免疫 HIV-1包膜蛋白在小鼠体内不能形成肿瘤 HIVAX；和2)开始更详细地评估免疫原性和 以优化疫苗的投放。 建议的商业应用：不可用

DESCRIPTION: (From the applicant's abstract) Cytotoxic T cell (CTL) immunity is considered to play a major role in reducing viral load early in HIV infection, and in slowing the rate of progression to AIDS. However, most of the current HIV vaccines in advanced human clinical trials, those consisting of HIV-derived proteins or killed virus, elicit strong antibody responses but are poor at inducing CTL-mediated immunity. We have developed a novel vaccine delivery system, termed HIVAX, consisting of non-pathogenic Baker s yeast, (Saccharomyces cerevisiae) which we have engineered to express the HIV-1 gp160 envelope protein. Preliminary studies in mice and pig-tailed macaques have revealed several important characteristics of our vaccine: 1) it stimulates both CTL- mediated and humoral immunity; 2) it does not require co-administration of adjuvants; 3) it contains no infectious material; 4) it appears to immunize when given orally;and 5) it can be engineered using recombinant DNA technology to express three or more protein antigens. In this proposal the investigator will: 1) determine whether vaccine elicits protective immunity in mice by showing that tumor cells expressing the HIV-1 envelope protein fail to form tumors in mice vaccinated with HIVAX; and 2) begin to evaluate in greater detail the immunogenicity and to optimize delivery of the vaccine. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE